What are the NCCN guidelines on consolidation therapy for the treatment of acute promyelocytic leukemia (APL)?

Updated: May 03, 2019
  • Author: Sandy D Kotiah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

For consolidation therapy , NCCN recommends basing the choice of regimen on the agents used for induction therapy. For example, patients who received all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) would continue to receive ATRA/ATO, while those treated with ATRA plus chemotherapy would for the most part continue to receive those agents. In some cases, mitoxantrone may be added. [14]  

NCCN guidelines note that the role of maintenance therapy remains uncertain, especially for patients with low-risk APL who achieve molecular remission at the end of consolidation treatment. Most of the studies demonstrating benefit from maintenance therapy were conducted before the introduction of ATRA, ATO, or cytarabine for consolidation. [14]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!